I Peace has invested over $10 million to expand its Palo Alto, California plant, tripling capacity to manufacture iPS and iPSC-derived differentiated cells. I Peace, a contract development manufacturing organization (CDMO) start-up, has tripled its capacity to produce induced pluripotent stem (iPS) cells and induced pluripotent stem cells (iPSC) by expanding its facility. The firm claims that the plant expansion will meet the demand for iPS cells from pharmaceutical companies and cell therapy manufacturers, as well as providing individuals with…

Catalent has expanded its Limoges, France site to fulfil clinical biologics formulation development and drug product fill/finish services. Contract development manufacturing organization (CDMO) Catalent announced its plans to invest $30 million in July 2020. Now, the firm has completed the project and says the Limoges plant will widen its global network, with clinical development through to clinical supply services and small-scale commercial manufacturing. “Catalent continues to look for ways to support its customers as they advance projects to the clinic…

Stevanato Group says its decision to acquire a facility in Zhangjiagang, China is part of its growth strategy and aim to deliver supply chain security. Stevanato, a provider of drug delivery, drug containment, and diagnostic solutions to the life sciences industry, has acquired a facility located close to its plant in the Jiangsu Zhangjiagang Economic and Technical Development Zone. “[Our] facility in Zhangjiagang will support the production of high-value solutions, such as pre-sterilized EZ-fill syringes and vials, meeting the growing…

Nutcracker Therapeutics has raised $167 million in Series C financing to expand its mRNA pipeline and refine its RNA platform. Nutcracker focuses on developing RNA therapeutics using its biochip-based manufacturing platform. The firm claims the financing, led by ARCH Venture Partners, will enable the company to grow its pipeline of messenger RNA (mRNA) medicines for cancer and advance its platform technology. According to Nutcracker, producing RNA-based therapeutics with scalability and speed has remained a constant challenge in the industry. To…

The $97 million investment will expand Thermo Fisher’s bioanalytical laboratory operations into three locations in the Greater Richmond, Virginia region. According to Thermo Fisher Scientific, the decision to expand its clinical research business is in response to increased demand for its services. The investment will see the firm add nearly 150,000 square feet to its Richmond area operations. The laboratories in this location were gained through the firm’s acquisition of contract research organization (CRO) PPD last year. The company is…

The UK government has pledged £260 million to bolster healthcare research, £60 million of which will be used to expand manufacturing capabilities. At the beginning of this month, the UK government announced that £260 million ($339 million) will be invested into the life sciences industry. The £60 million ($78 million) dedicated to expanding manufacturing services will support cell and gene therapies, medical devices, and commercial scale production investments by various companies. The investment for manufacturing fundings will be distributed through…